FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
This article was originally published in PharmAsia News
SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality
You may also be interested in...
EU draft guidance calls for greater clarity on the source of API, putting many Chinese manufacturers in a tough position.
SHANGHAI - China's State FDA revised its Good Manufacturing Practices Guidelines, and is asking for industry feedback on how the guidelines would affect local pharmaceutical companies, SFDA Deputy Director Wu Zhen said during a forum on drug safety and healthcare reform in Beijing April 28
U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress